Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 24% Improvement Relative Risk Hospitalization (b) 55% c19hcq.org Cordtz et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 29,440 patients in Denmark Study underpowered to detect differences Cordtz et al., Rheumatology, doi:10.1093/rheumatology/keaa897 Favors HCQ Favors control
Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark
Cordtz et al., Rheumatology, doi:10.1093/rheumatology/keaa897
Cordtz et al., Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a.., Rheumatology, doi:10.1093/rheumatology/keaa897
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 58,052 rheumatic disease patients in Denmark showing that RA patients have a higher risk of COVID-19 hospitalization in general. HCQ treated patients show lower risk, although this is not statistically significant with only 3 hospitalizations for HCQ treated patients.
HR 0.76 [0.23-2.52] time-dependent exposure model
HR 0.45 [0.11-1.92] time-fixed exposure model
Although the 24% lower hospitalization is not statistically significant, it is consistent with the significant 16% lower hospitalization [6‑24%] from meta analysis of the 59 hospitalization results to date.
risk of hospitalization, 24.0% lower, HR 0.76, p = 0.67, treatment 3 of 2,722 (0.1%), control 38 of 26,718 (0.1%), NNT 3124, adjusted per study, time-dependent exposure model.
risk of hospitalization, 55.0% lower, HR 0.45, p = 0.28, treatment 3 of 2,722 (0.1%), control 38 of 26,718 (0.1%), adjusted per study, time-fixed exposure model.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cordtz et al., 28 Dec 2020, retrospective, population-based cohort, Denmark, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Rheumatology Rheumatology 2021;60:SI59–SI67 doi:10.1093/rheumatology/keaa897 Advance Access publication 28 December 2020 Original article Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark Objectives. To estimate the incidence of COVID-19 hospitalization in patients with inflammatory rheumatic disease (IRD); in patients with RA treated with specific DMARDs; and the incidence of severe COVID-19 infection among hospitalized patients with RA. Methods. A nationwide cohort study from Denmark between 1 March and 12 August 2020. The adjusted incidence of COVID-19 hospitalization was estimated for patients with RA; spondyloarthritis including psoriatic arthritis; connective tissue disease; vasculitides; and non-IRD individuals. Further, the incidence of COVID-19 hospitalization was estimated for patients with RA treated and non-treated with TNF-inhibitors, HCQ or glucocorticoids, respectively. Lastly, the incidence of severe COVID-19 infection (intensive care, acute respiratory distress syndrome or death) among hospital-admitted patients was estimated for RA and non-IRD sp - individudals. Results. Patients with IRD (n ¼ 58 052) had an increased partially adjusted incidence of hospitalization with COVID-19 compared with the 4.5 million people in the general population [hazard ratio (HR) 1.46, 95% CI: 1.15, 1.86] with strongest associations for patients with RA (n ¼ 29 440, HR 1.72, 95% CI: 1.29, 2.30) and vasculitides (n ¼ 4072, HR 1.82, 95% CI: 0.91, 3.64). There was no increased incidence of COVID-19 hospitalization associated with TNF-inhibitor, HCQ nor glucocorticoid use. COVID-19 admitted patients with RA had a HR of 1.43 (95% CI: 0.80, 2.53) for a severe outcome. Conclusion. Patients with IRD were more likely to be admitted with COVID-19 than the general population, and COVID-19 admitted patients with RA could be at higher risk of a severe outcome. Treatment with specific DMARDs did not affect the risk of hospitalization. Key words: rheumatoid arthritis, epidemiology, viruses, DMARDs, biological therapies, immunosupressants Rheumatology key messages Patients with IRD had higher incidence of COVID-19 hospitalisation compared with the general population of Denmark. Among patients with RA, the COVID-19 hospitalisation rates were not higher among those treated with hydroxychlorquine, TNF-inhibitor or glucocorticoids. . COVID-19 admitted patients with RA had a tendency towards a higher incidence of severe outcome, but this was not statistically significant. . . 1 Department of Rheumatology, Aalborg University Hospital, Aalborg, 2Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte Hospital, Hellerup, 3Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, 4Department of Clinical Medicine, Aalborg University, Aalborg, 5Department of Infectious Diseases, Aalborg University Hospital, Aalborg, 6Department of Cardiology, Nordsjællands Hospital, Hillerod and 7The DANBIO Register, Denmark Submitted 10 November 2020; accepted 8 December 2020 Correspondence to: René Cordtz, Department of Rheumatology, Aalborg University Hospital, Reberbansgade 15, DK-9000 Aalborg, Denmark. E-mail: r.cordtz@rn.dk//rcordtz@gmail.com *René Cordtz and Jesper Lindhardsen contributed equally to this study. C The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit